The effectiveness of rPMS therapy on upper trapezius muscle in subacute MPS: A double-blind randomized controlled trial
- Conditions
- Patients with subacute MPS on Upper trapezius musclerPMS,MPS
- Registration Number
- TCTR20200924003
- Lead Sponsor
- Department of Medical Services (DMS), MOPH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 72
1.Age 18 to 65 years
2.The patients who were diagnosed myofascial pain syndrome by the physiatrist
2.1 According to Simon’s Diagnostic Criteria*
2.2 Pain duration; 2 weeks to 3 months
2.3 At least 1 active trigger point at upper trapezius muscle
3.All patients are consented to join in the protocol
1.Cervical radiculopathy or myelopathy ,Inflammatory joint disease (AS, RA, and SLE) by history taking and physical examination
2.History of neck trauma and/or surgery
3.Pregnancy
4.Metallic implants (clips, cardiac valves, pacemakers)
5.Experience of receiving rPMS at upper trapezius muscle
6.Using any NSAIDs , opioids, and cannabis within 4 weeks before enrollment to the study
7.Received any treatment of myofascial trigger point at upper trapezius muscle (manual therapies, physical modalities) within 4 weeks before enrollment to the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pain intensity score 0, 2, 4wk 10cm VAS pain
- Secondary Outcome Measures
Name Time Method pressure pain threshod (PPT) scale 0, 2, 4 wk Manual Algometry (FPK-20),Neck Disability Index (NDI) -Thai version 0, 2, 4 wk Questionnaire - Thai version,(Relapse-free) mean survival time 12 wk NRS pain, call back if pain relapse with 12 wk,Survival experience (between group) 12 wk statistic method